We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CytoDyn Reports Top-Line Data From Phase II Coronavirus Study
Read MoreHide Full Article
CytoDyn Inc. (CYDY - Free Report) announced top-line results from its recently completed, randomized, double-blind, phase II study evaluating the efficacy and safety of leronlimab in patients with mild-to-moderate symptoms caused by COVID-19 infection.
Shares of the company fell 13.5% following the news as the investors were not impressed with the results. However, shares of the company have soared 316% year to date against the industry’s decline of 5.6%.
In the study, the primary endpoint showed early clinical improvement in symptom score at day 3 in patients receiving leronlimab. At day 3, more patients treated with leronlimab reported improvement in total clinical symptom score compared to the placebo group (90% on leronlimab arm versus 71% on placebo).
Leronlimab also demonstrated statistically significant improvement versus placebo in key secondary efficacy endpoint, National Early Warning Score 2 (NEWS2) scale. NEWS2 (the latest version) is being used as an endpoint in several other COVID-19 studies. It measures clinical parameters, including respiratory rate, oxygen saturation, supplemental oxygen, temperature, systolic blood pressure, heart rate and level of consciousness.
Treatment with leronlimab demonstrated reductions in both serious adverse events as well as predictors of pulmonary collapse in patients with mild-to-moderate COVID-19.
The company will request immediate approval of leronlimab for this population of COVID-19 patients, not only in the United States but also in the U.K. and other countries around the world.
Leronlimab is an investigational, humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases and other diseases, including NASH. The FDA has granted a Fast Track designation to leronlimab for two potential indications of deadly diseases —one as a combination therapy with HAART for HIV-infected patients and another for metastatic triple-negative breast cancer.
In July 2020, the company reported impressive results from the phase II COVID-19 study. The results showed that 39% of patients in placebo arm as compared to only 14% in leronlimab arm reported serious adverse events (SAEs), which were unrelated to leronlimab.
At this time, there are minimal treatment options for COVID-19. A potential approval of leronlimab will be a huge breakthrough to meet this unmet medical need.
Meanwhile, several marketed drugs like Incyte and Novartis’ (NVS - Free Report) JAK1/JAK2 inhibitor, Jakafi; AstraZeneca’s (AZN - Free Report) BTK inhibitor, Calquence; and Amgen’s (AMGN - Free Report) PDE4 inhibitor, Otezla, among others, are being evaluated to treat respiratory complications associated with COVID-19, which is the need of the hour.
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2020? Last year's 2019 Zacks Top 10 Stocks portfolio returned gains as high as +102.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Image: Bigstock
CytoDyn Reports Top-Line Data From Phase II Coronavirus Study
CytoDyn Inc. (CYDY - Free Report) announced top-line results from its recently completed, randomized, double-blind, phase II study evaluating the efficacy and safety of leronlimab in patients with mild-to-moderate symptoms caused by COVID-19 infection.
Shares of the company fell 13.5% following the news as the investors were not impressed with the results. However, shares of the company have soared 316% year to date against the industry’s decline of 5.6%.
In the study, the primary endpoint showed early clinical improvement in symptom score at day 3 in patients receiving leronlimab. At day 3, more patients treated with leronlimab reported improvement in total clinical symptom score compared to the placebo group (90% on leronlimab arm versus 71% on placebo).
Leronlimab also demonstrated statistically significant improvement versus placebo in key secondary efficacy endpoint, National Early Warning Score 2 (NEWS2) scale. NEWS2 (the latest version) is being used as an endpoint in several other COVID-19 studies. It measures clinical parameters, including respiratory rate, oxygen saturation, supplemental oxygen, temperature, systolic blood pressure, heart rate and level of consciousness.
Treatment with leronlimab demonstrated reductions in both serious adverse events as well as predictors of pulmonary collapse in patients with mild-to-moderate COVID-19.
The company will request immediate approval of leronlimab for this population of COVID-19 patients, not only in the United States but also in the U.K. and other countries around the world.
Leronlimab is an investigational, humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases and other diseases, including NASH. The FDA has granted a Fast Track designation to leronlimab for two potential indications of deadly diseases —one as a combination therapy with HAART for HIV-infected patients and another for metastatic triple-negative breast cancer.
In July 2020, the company reported impressive results from the phase II COVID-19 study. The results showed that 39% of patients in placebo arm as compared to only 14% in leronlimab arm reported serious adverse events (SAEs), which were unrelated to leronlimab.
At this time, there are minimal treatment options for COVID-19. A potential approval of leronlimab will be a huge breakthrough to meet this unmet medical need.
Meanwhile, several marketed drugs like Incyte and Novartis’ (NVS - Free Report) JAK1/JAK2 inhibitor, Jakafi; AstraZeneca’s (AZN - Free Report) BTK inhibitor, Calquence; and Amgen’s (AMGN - Free Report) PDE4 inhibitor, Otezla, among others, are being evaluated to treat respiratory complications associated with COVID-19, which is the need of the hour.
CytoDyn currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
CytoDyn Inc. Price
CytoDyn Inc. price | CytoDyn Inc. Quote
Zacks Top 10 Stocks for 2020
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2020? Last year's 2019 Zacks Top 10 Stocks portfolio returned gains as high as +102.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Access Zacks Top 10 Stocks for 2020 today >>